In the latest close session, Eli Lilly (LLY) was up +1.82% at $1,008.39. This move outpaced the S&P 500's daily gain of 0.83%. Elsewhere, the Dow gained 0.5%, while the tech-heavy Nasdaq added 1.38%.

With short-term returns turning negative, analysts are reassessing Lilly's high valuation, reminding the market that even ...

Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.

Eli Lilly's soaring stock price has sparked 2026 split speculation. Here's what a potential LLY split could mean and what investors should consider now.

Eli Lilly's market share in obesity drugs exceeds 60%, but further gains may be capped as competition escalates. Read why LLY ...

Eli Lilly (LLY) stock holds Morgan Stanley's $1,313 target as Mounjaro and Zepbound prescriptions rise week-over-week, ...

Eli Lilly (LLY) has been drawing investor attention after a stretch of mixed share performance, with the stock showing negative returns over the past week, month, and past 3 months, despite a positive ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic ...